Kura Oncology (NASDAQ:KURA) Earns Outperform Rating from Wedbush

Kura Oncology (NASDAQ:KURA)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a research note issued on Thursday,RTT News reports. They presently have a $36.00 price objective on the stock. Wedbush’s target price would indicate a potential upside of 364.52% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. Jefferies Financial Group reduced their target price on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday, November 21st. BTIG Research lowered Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday, February 6th. Scotiabank lowered their price target on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. Bank of America lowered their price target on Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a report on Friday, November 22nd. Finally, TD Cowen reiterated a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $27.13.

Kura Oncology Price Performance

NASDAQ:KURA traded down $0.02 on Thursday, reaching $7.75. 357,742 shares of the company’s stock traded hands, compared to its average volume of 1,584,997. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a 50-day simple moving average of $8.19 and a 200-day simple moving average of $13.92. The firm has a market cap of $602.67 million, a PE ratio of -3.28 and a beta of 0.78. Kura Oncology has a 12 month low of $6.98 and a 12 month high of $24.17.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million. Equities research analysts forecast that Kura Oncology will post -2.44 earnings per share for the current year.

Insider Transactions at Kura Oncology

In other news, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at $694,078.91. This represents a 5.31 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,729 shares of company stock valued at $92,307 in the last ninety days. 5.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Barclays PLC lifted its stake in Kura Oncology by 104.5% in the 3rd quarter. Barclays PLC now owns 165,484 shares of the company’s stock valued at $3,234,000 after buying an additional 84,563 shares in the last quarter. SG Americas Securities LLC purchased a new position in Kura Oncology in the 4th quarter valued at about $436,000. Moody Aldrich Partners LLC lifted its stake in Kura Oncology by 42.3% in the 4th quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company’s stock valued at $1,251,000 after buying an additional 42,712 shares in the last quarter. Harbor Capital Advisors Inc. lifted its stake in Kura Oncology by 4.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock valued at $430,000 after buying an additional 2,076 shares in the last quarter. Finally, Jennison Associates LLC purchased a new position in Kura Oncology in the 4th quarter valued at about $623,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.